Since 2015, I-Mab Biopharma has been actively working on building external partnerships with academic institutions, biotech companies and global pharma to explore business opportunities.
Firstly, A Joint Discovery Laboratory by I-Mab and the Institute of Health Sciences, Chinese Academy of Sciences was established in 2015. The joint laboratory allows I-Mab to work directly with scientists in academia and translate some of the exciting science into discovery projects that may be applicable for further development as promising products.
Secondly, I-Mab has acquired innovative clinical assets for further clinical development to fulfill the unmet needs in China. Olamkicept acquired from Ferring is one of the examples. I-Mab is in active discussion with a few other global entities for similar opportunities. This strategy has significantly enhanced the Company's ability to build a globally competitive pipeline of innovative biologics for the global market with an emphasis on addressing the unmet need in China.
Thirdly, I-Mab has been approached by global as well as China-based companies for the opportunities of licensing I-Mab's assets in various territories. Currently, discussions are on-going for three of the Company's globally competitive pre-clinical assets. Through these partnerships, I-Mab is able to expend its capabilities in discovery, e.g. the bi-specific antibody technology space and new targets, and in development. Some of the recent partnerships are highlighted in the table below.